Fig. 5
Netrin-1 contributes to angiogenesis in vivo in a CAM assay. a Representative images of distinct experimental approaches on CAM: DMEM (20 μL), Wharton’s jelly-derived mesenchymal stem cells (WJ-MSC) (1.5*106), 2F5 [a drug targeting Netrin-1 (NTN-1), 0.5 μg/μL] and CBO (a VEGF-receptor inhibitor, 50 μM), using for each condition approximately 15 eggs (scale bar = 1 mm). b Quantification of angiogenesis after 4 days of incubation in experimental conditions as indicated. Data correspond to the mean ± S.E.M. (WJ-MSC, n = 5, * p < 0.05 vs. DMEM, Φ p < 0.05 vs. WJ-MSC)